• Jacob C Jentzer, Brandon Wiley, Courtney Bennett, Dennis H Murphree, Mark T Keegan, Kianoush B Kashani, Malcolm R Bell, and Gregory W Barsness.
• Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
• Shock. 2020 Apr 1; 53 (4): 452-459.

BackgroundThe use of norepinephrine may be associated with better outcomes in some patients with shock. We sought to determine whether norepinephrine was associated with lower mortality in unselected cardiac intensive care unit (CICU) patients compared with other vasopressors, and whether patterns of vasopressor and inotrope usage in the CICU have changed over time.MethodsWe retrospectively evaluated consecutive adult patients admitted to a tertiary care hospital CICU from January 1, 2007 to December 31, 2015. Vasoactive drug doses were quantified using the peak Vasoactive-Inotropic Score (VIS). Temporal trends were assessed using the Cochran-Armitage trends test and multivariable logistic regression was used to determine predictors of hospital mortality.ResultsWe included 10,004 patients with a mean age of 67 ± 15 years; vasoactive drugs were used in 2,468 (24.7%) patients. Use of norepinephrine increased over time, whereas dopamine utilization decreased (P < 0.001 for trends). After adjustment for illness severity and other variables, the peak VIS was a predictor of hospital mortality across the entire population (unit odds ratio [OR] 1.013, 95% confidence interval [CI], 1.009-1.017, P < 0.001) and among patients receiving vasoactive drugs (OR 1.018, 95% CI, 1.013-1.022, P < 0.001). Among patients receiving vasoactive drugs, norepinephrine was associated with a lower risk of hospital mortality (OR 0.66, 95% CI, 0.49-0.90, P = 0.008) after adjustment for illness severity and peak VIS.ConclusionsVasoactive drug use in CICU patients has a dose-dependent association with short-term mortality. Use of norepinephrine in CICU patients is associated with decreased odds of death when compared with other vasoactive drugs.

23 keywords...

hide…